PL3777833T3 - Kompozycje inhibitorów dekarboksylazy dopa - Google Patents

Kompozycje inhibitorów dekarboksylazy dopa

Info

Publication number
PL3777833T3
PL3777833T3 PL20198371.5T PL20198371T PL3777833T3 PL 3777833 T3 PL3777833 T3 PL 3777833T3 PL 20198371 T PL20198371 T PL 20198371T PL 3777833 T3 PL3777833 T3 PL 3777833T3
Authority
PL
Poland
Prior art keywords
decarboxylase inhibitor
inhibitor compositions
dopa decarboxylase
dopa
compositions
Prior art date
Application number
PL20198371.5T
Other languages
English (en)
Polish (pl)
Inventor
Oron Yacoby-Zeevi
Original Assignee
Neuroderm Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53488380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3777833(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuroderm Ltd. filed Critical Neuroderm Ltd.
Publication of PL3777833T3 publication Critical patent/PL3777833T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20198371.5T 2014-03-13 2015-03-12 Kompozycje inhibitorów dekarboksylazy dopa PL3777833T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461952477P 2014-03-13 2014-03-13
US201461990967P 2014-05-09 2014-05-09

Publications (1)

Publication Number Publication Date
PL3777833T3 true PL3777833T3 (pl) 2024-03-25

Family

ID=53488380

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20198371.5T PL3777833T3 (pl) 2014-03-13 2015-03-12 Kompozycje inhibitorów dekarboksylazy dopa
PL15731727T PL3116475T3 (pl) 2014-03-13 2015-03-12 Kompozycje inhibitora dekarboksylazy dopa

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL15731727T PL3116475T3 (pl) 2014-03-13 2015-03-12 Kompozycje inhibitora dekarboksylazy dopa

Country Status (19)

Country Link
US (5) US10022320B2 (enExample)
EP (3) EP3116475B1 (enExample)
JP (2) JP6591995B2 (enExample)
CN (1) CN106413754B (enExample)
AU (1) AU2015228369B2 (enExample)
BR (1) BR112016021034A8 (enExample)
CA (1) CA2942244C (enExample)
DK (2) DK3116475T3 (enExample)
ES (2) ES2967693T3 (enExample)
FI (1) FI3777833T3 (enExample)
HR (2) HRP20201948T1 (enExample)
HU (2) HUE064818T2 (enExample)
IL (1) IL247668B (enExample)
MX (1) MX2016011837A (enExample)
PL (2) PL3777833T3 (enExample)
PT (2) PT3777833T (enExample)
RS (1) RS65060B1 (enExample)
RU (1) RU2684105C2 (enExample)
WO (1) WO2015136538A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3192500T (pt) 2009-05-19 2021-01-05 Neuroderm Ltd Composições para a administração contínua de inibidores da dopa decarboxilase
DK2640358T3 (en) 2010-11-15 2018-04-16 Neuroderm Ltd CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA-DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND COMPOSITIONS THEREOF
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
PL3777833T3 (pl) 2014-03-13 2024-03-25 Neuroderm Ltd. Kompozycje inhibitorów dekarboksylazy dopa
JP6415715B2 (ja) 2015-09-30 2018-10-31 デューク・ユニヴァーシティ アスコルベート製剤及び造影剤としての使用方法
WO2018154447A1 (en) * 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
TW202031265A (zh) 2018-11-15 2020-09-01 美商艾伯維有限公司 用於皮下投藥之醫藥調配物
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
CN111701024B (zh) * 2020-05-26 2022-05-24 上海京新生物医药有限公司 一种左旋多巴制剂及其制备方法及其应用
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
CN113396897B (zh) * 2021-07-26 2022-06-07 苏州华测生物技术有限公司 一种稳定生物基质中卡比多巴/左旋多巴的方法
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769424A (en) 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
AU6889274A (en) 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
US3936495A (en) 1973-11-27 1976-02-03 Merck & Co., Inc. Purification process
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4241082A (en) 1977-09-02 1980-12-23 Sankyo Company Limited Agents for promoting reproductive ability of domestic animals
JPS5450700A (en) 1977-09-28 1979-04-20 Sankyo Co Glazing agent of animal leather
JPS6021570B2 (ja) 1978-07-04 1985-05-28 三共株式会社 ド−パ類の高濃度製剤の製法
JPS56115749A (en) 1980-02-18 1981-09-11 Sagami Chem Res Center Dopa derivative
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4642316A (en) 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
DE3779500T2 (de) 1986-06-10 1993-01-21 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4832957A (en) 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4684666A (en) 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
IT1226902B (it) 1988-07-12 1991-02-21 Mini Ricerca Scient Tecnolog Processo per la sintesi del levodopa
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
CA2058975C (en) 1990-10-30 2000-06-06 Shuichi Kasai Antiinflammatory gel preparation
US5877176A (en) 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
CA2143070C (en) 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
DK0828513T3 (da) 1995-05-26 2004-04-13 Pfizer Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister
GB9523833D0 (en) 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
IL119417A (en) 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
AU1917899A (en) 1998-03-20 1999-10-18 Warner-Lambert Company Crystalline sodium phenytoin monohydrate
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
CA2327285C (en) 1998-05-15 2005-06-14 Warner-Lambert Company Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
US6274168B1 (en) 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
AU3490300A (en) 1999-03-12 2000-10-04 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US7479498B2 (en) 1999-08-23 2009-01-20 Phoenix Biosciences, Inc. Treatments for viral infections
US6348965B1 (en) 1999-09-24 2002-02-19 Henry Palladino Solid state fluorescence and absorption spectroscopy
SE0001151D0 (sv) 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition
US20020028799A1 (en) 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction
GB0017387D0 (en) 2000-07-14 2000-08-30 Pfizer Ltd Novel enzyme
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US20030119714A1 (en) 2000-12-15 2003-06-26 Naylor Alasdair Mark Treatment of male sexual dysfunction
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
IL159812A0 (en) 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
PL211116B1 (pl) 2001-10-19 2012-04-30 Idexx Lab Komozycja do podawania ssakowi związku farmakologicznie czynnego i sposób wytwarzania preparatu do wstrzyknięć
WO2003050261A2 (en) 2001-12-10 2003-06-19 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
ES2189682B1 (es) 2001-12-11 2004-04-01 Laboratorios Del Dr. Esteve, S.A. Preparacion bebible que comprende ketoprofeno y su empleo en el tratamiento de procesos que cursan con fiebre, inflamacion y/o dolor, en un colectivo de animales, de forma simultanea.
BR0309113A (pt) 2002-04-11 2005-02-01 Ranbaxy Lab Ltd Composições farmacêuticas de liberação controlada de carbidopa e levodopa e processo para a preparação das mesmas
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
JP4602903B2 (ja) 2002-10-10 2010-12-22 モルフォケム アクチェンゲゼルシャフト フュア コンビナトリシェ ヘミー 抗菌活性を有する新規化合物
EP1596808A4 (en) 2003-02-07 2007-04-04 Yissum Res Dev Co L-DOPA AMID DERIVATIVES AND THEIR USE
US8075919B2 (en) 2003-07-18 2011-12-13 Baxter International Inc. Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
ES2360759T3 (es) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
MXPA06002344A (es) * 2003-08-29 2006-05-19 Transform Pharmaceuticals Inc Composiciones farmaceuticas y metodo para usar levodopa y carbidopa.
US20050053669A1 (en) 2003-09-05 2005-03-10 Boehringer Ingelheim International Gmbh Administration form for the oral application of poorly soluble acidic and amphorteric drugs
RU2006118801A (ru) 2003-10-31 2007-12-10 Алза Корпорейшн (Us) Композиции и лекарственные формы для усиления всасывания габапентина и прегабалина
WO2005099678A1 (en) 2004-04-06 2005-10-27 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
HRP20160455T1 (hr) 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
WO2006037061A2 (en) 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
WO2006039691A2 (en) 2004-10-01 2006-04-13 The Research Foundation Of State University Of New York Morphine and morphine precursors
EP2335696A1 (en) 2005-06-08 2011-06-22 Orion Corporation An entacapone-containing oral dosage form
DE102006021872B4 (de) 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR20090057349A (ko) 2006-05-31 2009-06-05 솔베이 파머슈티컬스 게엠베하 레보도파／칼비도파의 ２４시간의 장기간 장내투여
PE20080669A1 (es) 2006-09-08 2008-07-18 Drugtech Corp Composicion de liberacion sostenida que comprende levodopa
CA2606658A1 (en) 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
EP2144663A4 (en) 2007-04-06 2011-06-22 Transform Pharmaceuticals Inc SYSTEMS AND METHODS FOR DISTRIBUTING A FLUID MEDICINE
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
KR101444979B1 (ko) * 2008-02-06 2014-10-07 욱크하르트 리미티드 생체 이용율이 개선된 엔타카폰, 레보도파 및 카르비도파의 약학 조성물
CN101669925B (zh) 2008-09-10 2011-08-10 天津药物研究院 干粉吸入剂、其制备方法和用途
WO2010055133A1 (en) 2008-11-14 2010-05-20 Neurosearch A/S Benzimidazole derivatives and their use for modulating the gabaa receptor complex
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
PT3192500T (pt) 2009-05-19 2021-01-05 Neuroderm Ltd Composições para a administração contínua de inibidores da dopa decarboxilase
CN101987081B (zh) 2010-07-16 2012-08-08 钟术光 一种控释制剂
KR101187064B1 (ko) 2010-07-18 2012-09-28 주식회사 바이오폴리메드 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체
US10150792B2 (en) 2010-11-08 2018-12-11 Synthonics, Inc. Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
WO2012066537A2 (en) 2010-11-15 2012-05-24 Neuroderm Ltd Compositions for transdermal delivery of active agents
DK2640358T3 (en) * 2010-11-15 2018-04-16 Neuroderm Ltd CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA-DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND COMPOSITIONS THEREOF
EP2648716A4 (en) 2010-12-10 2015-05-20 Synagile Corp PRODUCT COMPOSITIONS OF SUVUTABLY PERFUSABLE LÉVODOPA
WO2013061161A2 (en) 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
TR201204839A2 (tr) * 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
US20150217046A1 (en) 2012-06-05 2015-08-06 Synagile Corporation Dosing regimens for subcutaneously infusible acidic compositions
EP2854764B1 (en) 2012-06-05 2018-12-12 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
HUE056006T2 (hu) 2013-03-13 2022-01-28 Neuroderm Ltd Kombináció Parkinson-kór kezelésére
PL3777833T3 (pl) 2014-03-13 2024-03-25 Neuroderm Ltd. Kompozycje inhibitorów dekarboksylazy dopa
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
ES2739536T3 (es) 2014-10-21 2020-01-31 Abbvie Inc Profármacos de carbidopa y L-dopa y su uso para tratar la enfermedad de Parkinson
CA3006028A1 (en) 2015-11-24 2017-06-01 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide and uses thereof
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
WO2019038639A1 (en) 2017-08-21 2019-02-28 Neuroderm Ltd FREE LEOPODOPA CRYSTALLINE AMIDE BASE AND METHODS OF MAKING AND USING SAME
AR112472A1 (es) 2017-08-21 2019-10-30 Neuroderm Ltd Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas
AR112473A1 (es) 2017-08-21 2019-10-30 Neuroderm Ltd Proceso para preparar amida de levodopa purificada

Also Published As

Publication number Publication date
MX2016011837A (es) 2017-04-27
EP4299128A3 (en) 2024-04-17
ES2967693T3 (es) 2024-05-03
DK3777833T3 (da) 2023-12-18
PT3777833T (pt) 2024-01-09
JP6770158B2 (ja) 2020-10-14
WO2015136538A1 (en) 2015-09-17
EP3777833A1 (en) 2021-02-17
FI3777833T3 (fi) 2024-01-03
EP3116475A1 (en) 2017-01-18
DK3116475T3 (da) 2020-12-07
ES2836325T3 (es) 2021-06-24
JP2020011977A (ja) 2020-01-23
RU2016135952A3 (enExample) 2018-09-12
EP3116475B1 (en) 2020-11-04
AU2015228369A1 (en) 2016-10-27
US20150352212A1 (en) 2015-12-10
US10624839B2 (en) 2020-04-21
RU2684105C2 (ru) 2019-04-04
IL247668B (en) 2020-09-30
CA2942244A1 (en) 2015-09-17
CA2942244C (en) 2022-08-23
US20210038505A1 (en) 2021-02-11
HUE052642T2 (hu) 2021-05-28
EP3777833B1 (en) 2023-10-18
AU2015228369B2 (en) 2020-05-21
US20260102334A1 (en) 2026-04-16
HUE064818T2 (hu) 2024-04-28
PL3116475T3 (pl) 2021-02-08
HRP20231716T1 (hr) 2024-03-15
BR112016021034A8 (pt) 2021-06-29
US20230240980A1 (en) 2023-08-03
CN106413754B (zh) 2019-11-29
PT3116475T (pt) 2020-12-15
RS65060B1 (sr) 2024-02-29
IL247668A0 (en) 2016-11-30
US20190151233A1 (en) 2019-05-23
EP4299128A2 (en) 2024-01-03
JP6591995B2 (ja) 2019-10-16
CN106413754A (zh) 2017-02-15
JP2017507973A (ja) 2017-03-23
US10022320B2 (en) 2018-07-17
BR112016021034A2 (pt) 2017-08-15
RU2016135952A (ru) 2018-04-13
HRP20201948T1 (hr) 2021-01-22

Similar Documents

Publication Publication Date Title
IL277299B (en) Cyclopropylamines as lsd1 inhibitors
IL277167B (en) Cyclopropylamines as lsd1 inhibitors
PT3116475T (pt) Composições de inibidores de dopa-descarboxilase
SG11201704936SA (en) Corrosion inhibitor compositions for acidizing treatments
IL246362A0 (en) Novel glutaminase inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
ZA201704301B (en) Microencapsulated nitrification inhibitor compositions
GB201403536D0 (en) Inhibitor compounds
PT3227325T (pt) Composições inibidoras seletivas da sinalização trans de il-6
GB201411802D0 (en) Effervescent compositions
HUE050027T2 (hu) Antioxidáns készítmények
IL247921A0 (en) Glutaminase inhibitor compounds, preparations containing them and their uses
GB201408167D0 (en) Compositions
GB201406542D0 (en) Intumescent compositions
IL251479A0 (en) components
GB201420306D0 (en) Compositions
SG11201610860UA (en) Sweetener compositions
GB201401005D0 (en) Inhibitor
GB201501779D0 (en) NONOate compositions
GB201411470D0 (en) Effervescent compositions
GB201419849D0 (en) Compositions
GB201406863D0 (en) Compositions comprising variegin